Dhan Chand

Scientist

[Myriam Chalabi @MyriamChalabi]

Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in @NatureCancer @lab_kok
https://t.co/HbH5Mm2dvn

[Pashtoon Kasi MD, MS @pashtoonkasi]

Nothing against radiation☢️but if we can have #immunotherapy like BOT/BAL eradicate/cure cancer, we can set a similar paradigm for our patients with MSS🔵 #ColorectalCancer as is now the case for patients with MSI-High🔴 tumors and spare additional toxicity.

Now @cityofhope 👇🏽🙌🏽

[Jennifer Buell @jbuell01]

When the “coldest” tumors melt:
@MyriamChalabi breaks new ground (again) at #AACR25. NEOASIS Trial:
• 80% MPR in dMMR (70% pCR!)
• 60% MPR in pMMR
BOT/BAL are pushing ICB into non-immunogenic tumors.
#CancerImmunotherapy #BOT/BAL

[Amalya Sargsyan @amalsargsyan]

What a shift! In 2021, I was among people who loved reading @CancerWorldmag , now I authored the COVER story! 🤩

Huge honor and Motivation to Dream Big!

Discussing Role Of IOs - BOT + BAL & the impact beyond data in MSS colon cancer. Check it out ⬇️

https://t.co/T39qsvxjIg

[Dr. Marwan G. Fakih @mgfakih]

GI/ASCO: We presented our Phase 1 BOT/BAL with FOLFOX in MSS MCRC. 14 patients on the phase 1 study. 10 had prior Ox and 12 had prior chemo, yet ORR was 10/14 patients (majority of the pts had liver mets). The combination was safe with 2 doses of BOT + Q2w FOLFOXBEV/BAT

[A.n.n. @fireflyann]

ASCO #GI25
The future of immunotherapy in MSS colon cancer is here!

UNICORN trial results
Preoperative botensilimab (BOT) w or w/o balstilimab (BAL) for patients w/ resectable locally advanced pMMR or dMMR colon cancer:
NCT05845450
PI: @FilippoPietran4
https://t.co/O3W3YMvXCV

[Pashtoon Kasi MD, MS @pashtoonkasi]

🆕#GI25 abstracts now released! 📰 🗞️

Neoadjuvant #immunotherapy continues to impress! Building upon the paradigm shift of immunotherapy to earlier settings ➡️📈CURES🙌🏽

✅NEST🪺
✅UNICORN🦄
✅NICHE

These trials📚~80 treated. ✔️SAFE.
🔜Time for a phase-2/3.
@OncoAlert #CRCSM

[Cancer Discovery @CD_AACR]

From the December issue: Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy https://t.co/E2eGyQ3iFk

By @dhanschand and colleagues @Agenus_Bio

[OncoDaily @oncodaily]

📢Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers

Botensilimab is poised to revolutionize the treatment of MSS colorectal cancer, offering promising results and a new hope for patients with limited options.
@dhanschand @Agenus_Bio

https://t.co/uaXGSNAIkd

#Cancer #Oncology #OncoDaily #MedEd #MedX #MedNews #Medicine #ColorectalCancer #CancerTreatment

[Dhan Chand @dhanschand]

Excited to be presenting at the #GlobalCancerMovement conference today!

Join me to discuss our groundbreaking work on Botensilimab in treating immunologically 'cold' and treatment-refractory #colorectal #cancer

#Immunotherapy @Agenus_Bio

Sign up

https://t.co/vfmKBtVRSC

[Dhan Chand @dhanschand]

Excited to share our latest research at #SITC2024!

Priya Iyer presents AGEN1721: a novel Fc-enhanced bifunctional antibody targeting FAP & TGFβ. Depletes FAP+ CAFs & neutralizes TGFβ to transform immune-excluded tumors.

Visit Poster #1355 today! #immunotherapy #cancer"

[Casey Ager @caseyager]

Also, this new class of next-gen CTLA4 drugs has multiple potential beneficial effects beyond simple Treg depletion. Beautiful recent data from @Agenus_Bio @dhanschand supports many of our findings on this front!

https://t.co/9Q3wbWaj04

(15/17)

[Dhan Chand @dhanschand]

@IdoAmitLab Thank you @IdoAmitLab. Your Nat Cancer 2022 paper on the role of Fc driving myeloid activation was indeed influential in how we interpreted our findings with botensilimab, an Fc-enhanced anti-CTLA-4.

[Jennifer Buell @jbuell01]

📢 NCI Announces Availability of Botensilimab for Clinical Development

Botensilimab is available through the NCI CTEP program in collaboration with Agenus. Strong LOIs for clinical studies are being evaluated. https://t.co/PIlLrSVg4P

[Jennifer Buell @jbuell01]

🔥🔥🔥congrats @Agenus_Bio breaking through the most frequent and aggressive #MSSCRC cancers. Pathbreaking @pashtoonkasi #BOT

[Nature Medicine @NatureMedicine]

2 new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated & elicited encouraging clinical responses in patients with relapsed/refractory microsatellite stable #ColorectalCancer @DrElkhoueiry @DanaFarber @MDAndersonNews @cityofhope
https://t.co/4e1BBEOfxJ

[Dhan Chand @dhanschand]

Just published in @NatureMedicine.

Botensilimab, a multifunctional Fc-enhanced anti-CTLA-4 antibody is transforming the treatment landscape for patients with MSS colorectal cancer.

#CancerResearch #CRC #Immunotherapy

https://t.co/68wcYXGZ5f

[Myriam Chalabi @MyriamChalabi]

Ecstatic and proud to share the NICHE-2 results, now published in @NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. @HaanenJohn
https://t.co/h7xgmjOfjz

[LUNGevity Foundation @LUNGevity]

New dual TIGIT & CD96 blocking immunotherapy drug effective in activating anti-cancer immune response in mouse models. Efficacy increased when combined with PD-L1 blocking immunotx. Phase 1/2 trial that includes patients w/ #NSCLC ongoing #AACR24

[Dhan Chand @dhanschand]

Today at @AACR we demonstrated the power of MiNK's iNKTs to overcome the limitations of immune checkpoint blockade therapy to eliminate MSS colorectal liver metastases. Potential to be a powerful combination partner with Bot/BAL. #AACR24, #Immunotherapy. @MiNK_iNKT @Agenus_Bio.